1Baldwin AS.Control of oncogenesis and cancer therapy resistance by the tran-scription factor NF- KB[].The Journal of Clinical Investigation.2001
2Baeuerie PA,Baltimore D.NF- KB : ten years after[].Cell.1996
3Johnson C,Antwerp DV,Hope TJ.An N- terminal nuclear export signal is re-quired for the nucleocytoplasmic shuttling of 1KB-[].EMBO Journal.1999
4Siebenlist U,Franzoso G,Brown K,et al.Structure, regulation and functionof NF- KB[].Annual Review of Cell Biology.1994
5Latimer M,Ernst MK,Dunn LL,et al.The N- Terminal domain of Motmasks the nuclear localization signal ( s) of p50 and e - Rel homodimers[].Molecular and Cellular Biology.1998
6Meng L,Mohan R,Kwok BH,ei al.Epoxomicin, a potent and selective pro-teasome inhibitor, exhibits in vivo antiinflammatory activity[].Proceedings of the National Academy of Sciences of the United States of America.1999
7Yamamoto Y,Gaynor RB.Therapeutic potential of inhibition of the NF - KB pathway in the treatment of inflammation and cancer[].Journal of Clinical Investment.2001
8Tomita N,Morishita R,Lan HY,et al.In vivo administration of a nuclear transcription factor- kappaB decoy suppresses experimental crescentic glomer-ulonephritis[].Journal of the American Society of Nephrology.2000
9Mattson MP,Camandola S.NF- kappaB in neuronal plasticity and neurode-generative disorders[].The Journal of Clinical Investigation.2001
10Zandi E,Chen Y,Karin M,et al.Direct phosphorylation of IkappaB by IKKalpha and IKKbeta; discrimination between free and NF- kappaB- bound substrate[].Science.1998
